Dova Pharmaceuticals Inc (NASDAQ:DOVA) Given Consensus Recommendation of “Hold” by Analysts

Dova Pharmaceuticals Inc (NASDAQ:DOVA) has been assigned a consensus rating of “Hold” from the nine ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $26.42.

Several analysts have recently weighed in on DOVA shares. ValuEngine downgraded Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. HC Wainwright downgraded Dova Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $45.00 to $27.50 in a report on Monday, September 30th. Zacks Investment Research upgraded Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 14th. BidaskClub downgraded Dova Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 6th. Finally, Wedbush lowered Dova Pharmaceuticals from an “outperform” rating to a “neutral” rating and upped their target price for the company from $24.00 to $29.00 in a research report on Friday, October 4th.

Shares of DOVA stock opened at $28.04 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.64 and a quick ratio of 5.37. The company’s fifty day moving average price is $28.11 and its two-hundred day moving average price is $18.72. The firm has a market capitalization of $807.55 million, a P/E ratio of -10.78 and a beta of 2.74. Dova Pharmaceuticals has a 12 month low of $5.62 and a 12 month high of $28.54.

In other Dova Pharmaceuticals news, VP Kevin Laliberte sold 3,100 shares of the firm’s stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $20.00, for a total transaction of $62,000.00. Also, insider Jason Hoitt sold 2,387 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $28.00, for a total transaction of $66,836.00. Insiders have sold a total of 14,458 shares of company stock worth $379,497 over the last quarter. 60.30% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of the company. Capital Investment Advisory Services LLC grew its stake in Dova Pharmaceuticals by 222.2% in the second quarter. Capital Investment Advisory Services LLC now owns 2,900 shares of the company’s stock worth $45,000 after purchasing an additional 2,000 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Dova Pharmaceuticals by 34.1% in the 2nd quarter. Vanguard Group Inc. now owns 691,318 shares of the company’s stock worth $9,748,000 after acquiring an additional 175,605 shares in the last quarter. DekaBank Deutsche Girozentrale grew its position in shares of Dova Pharmaceuticals by 63.9% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 21,800 shares of the company’s stock worth $293,000 after acquiring an additional 8,500 shares in the last quarter. Meeder Asset Management Inc. increased its holdings in shares of Dova Pharmaceuticals by 231.5% in the 3rd quarter. Meeder Asset Management Inc. now owns 988 shares of the company’s stock valued at $27,000 after acquiring an additional 690 shares during the last quarter. Finally, Morgan Stanley increased its holdings in shares of Dova Pharmaceuticals by 102.2% in the 2nd quarter. Morgan Stanley now owns 325,998 shares of the company’s stock valued at $4,596,000 after acquiring an additional 164,761 shares during the last quarter. 33.03% of the stock is currently owned by institutional investors and hedge funds.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Further Reading: Cost of Debt

Analyst Recommendations for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit